Printer Friendly

THE MINNESOTA BIOTECHNOLOGY ASSOCIATION GETTING MINNESOTA READY FOR BIOTECHNOLOGY

 THE MINNESOTA BIOTECHNOLOGY ASSOCIATION
 GETTING MINNESOTA READY FOR BIOTECHNOLOGY
 ST. PAUL, Minn., Jan. 6 /PRNewswire/ -- Minnesota is one of a handful of regions in the United States with the resources necessary to realize the promise of biotechnology.
 Biotechnology, the set of research and production techniques derived from modern biology that are used by a broad range of industries, will play a pivotal role in the nation's economic growth in the coming century -- particularly to the citizens and companies of Minnesota.
 There are over 100 biotechnology companies in Minnesota, that generated over $1.8 billion in sales in 1991 and employed 16,500 people -- mostly in Minnesota. The state is home to such world leaders as Medtronic, SciMed Life Systems, Schneider USA, Bioplasty and CNS, all experiencing a 50 percent growth in revenues between 1989 and 1990 -- while extensively utilizing biotechnology as an integral tool for growth.
 The Minnesota Biotechnology Association was formed in March 1991 in recognition of the need for a unified voice to address public policy, education, public information, research, business climate, safety and job issues related to biotechnology. The association was established to represent the interests of companies and other organizations involved in biotechnology in Minnesota because of the increasing need to provide accurate information to the media, public officials, groups and individuals surrounding often complex issues.
 The association is comprised of over 20 member companies, and includes American Crystal Sugar, Cargill, Monsanto, Pillsbury/Grand Metropolitan, Upjohn and the University of Minnesota. These companies are active in a range of endeavors which involve various aspects of biotechnology including agricultural products, pharmaceuticals, food manufacturing, instrumentation and education.
 The founding board of directors for the association includes Dr. Warren Springer of Sustane, Vaun Olhausen of UpJohn/Asgrow and Dr. Jeffrey Tate, special assistant to the director at Biological Process Technology Institute at the University of Minnesota. The association objective is to help foster a climate conducive to the advancement of responsible biotechnology in Minnesota.
 "The 'biotechnology industry' is a misnomer, because there are few companies in Minnesota dedicated solely to this new technology," stated University of Minnesota's Tate, "rather, the tools of biotechnology have become an integral part of the business activity of both the region's biggest and fastest growing companies. The use of biotechnology's tools plays an important role in the economic success of Minnesota companies, large and small, now and will become an ever larger factor in the coming years."
 The Minnesota Biotechnology Association is a non-profit trade association working to ensure that Minnesotans benefit from the responsible development of biotechnology. The association seeks to educate the public by providing accurate information on biotechnology issues and promoting research practices which protect the environment and human and animal well-being. It acts as a legislative regulatory resource and as a forum for its members large and small.
 Association members contribute to the development of the organization through participation in committees which address public relations, research, education and legislative issues.
 -0- 01/06/92
 /CONTACT: Dr. Jeffrey Tate of Minnesota Biotechnology Association, 612-625-2285/ CO: Minnesota Biotechnology Association ST: Minnesota IN: MTC SU:


DS -- MN003 -- 6946 01/06/92 13:28 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 6, 1992
Words:521
Previous Article:BRUNSWICK PLANT CITED FOR NRC VIOLATION
Next Article:ECHO BAY SELLS 30 PERCENT INTEREST IN LAMEFOOT PROPERTY NEAR KETTLE RIVER JOINT VENTURE TO CROWN RESOURCES
Topics:


Related Articles
REGENEREX, INC. APPOINTS PRESIDENT, COO TO LEAD DEVELOPMENT PROGRAM FOR ARTIFICIAL LIVER
BIO Names Minnesota's Carlson 'Outstanding Governor of the Year'
Japanese Pharmaceutical/Life Science Firms Continue Search for Midwest Biotech Partners at September 10 Chicago Summit; Hundreds to Gather for...
Japan, Midwest Biotechnology Industry Leaders Identify Steps for Greater Collaboration Between Countries; Proposals Developed at Chicago Meeting.
BIO Mid-America VentureForum Planned for St. Louis.
Economic Impact Study Released on Minnesota Partnership for Biotechnology And Medical Genomics; Mid-Range Scenario Suggests 4,000 New Jobs and Nearly...
Symposium to Identify Opportunities for Collaboration Between Minnesota And Japanese Medical Device and Pharma Companies; March 23 Minneapolis Event...
Minnesota and Japanese Medical Device, Pharma Companies Seek Ways to Collaborate at March 23 Symposium; Common Goals Seen Between State Plans for...
Missouri Biotechnology Association Tells Minnesota Companies 'You're Welcome Here'; Minnesota Industry Being Targeted by Own Governor.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters